Can liraglutide benefit cardiovascular health in patients with Type 2 diabetes?

The glucagon-like peptide-1 receptor agonist liraglutide may help improve cardiovascular health in patients with Type 2 diabetes.

In a study, published in the Journal of the American College of Cardiology, researchers used cardiovascular magnetic resonance imaging, 31 phosphorous magnetic resonance spectroscopy and the six-minute walk test to evaluate the cardiovascular health of 41 patients with Type 2 diabetes who received either liraglutide or pioglitazone.

After a follow-up of 16 weeks, the researchers discovered that liraglutide improved the patients’ myocardial perfusion, energetics and exercise capacity compared with pioglitazone.

The findings may provide insights into the mechanisms responsible for the cardiovascular benefits of GLP-1 receptor agonists such as liraglutide in this patient population.

Read more: Journal of the American College of Cardiology

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.